Management of Cytopenias during Chronic Hepatitis C Therapy

Alyson N. Fox, Vinod K. Rustgi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Combination therapy with peginterferon alfa and ribavirin is the mainstay of therapy for chronic hepatitis C. The use of these agents is often limited by adverse events, of which cytopenias are common. The development of haematological abnormalities often results in drug dose reduction or discontinuation, which limits efficacy of achieving virological outcomes. Management of these haematological abnormalities with growth factors offers the possibility of therapy continuation.

Original languageEnglish (US)
Title of host publicationClinical Dilemmas in Viral Liver Disease
PublisherWiley-Blackwell
Pages65-69
Number of pages5
ISBN (Print)9781405179058
DOIs
StatePublished - Mar 10 2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General Medicine

Keywords

  • Anaemia
  • Hepatitis C
  • Neutropenia
  • Peginterferon
  • Ribavirin
  • Thrombocytopenia

Fingerprint

Dive into the research topics of 'Management of Cytopenias during Chronic Hepatitis C Therapy'. Together they form a unique fingerprint.

Cite this